{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:27:36Z","timestamp":1747171656546,"version":"3.40.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.toxlet.2018.10.007","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T13:33:22Z","timestamp":1539178402000},"page":"164-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A new, sensitive and versatile assay for quantitative determination of \u03b1-fluoro-\u03b2-alanine (AFBA) in human urine by using the reversed-phase ultrahigh performance-tandem mass spectrometry (rp-UHPLC\u2013MS\/MS) system"],"prefix":"10.1016","volume":"298","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9103-7367","authenticated-orcid":false,"given":"Cristina","family":"Sottani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Grignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Zaratin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Santorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Studioso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Lonati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo A.","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"Pastoris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Negri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Cottica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2018.10.007_bib0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/135475098231390","article-title":"\u03b1-fluoro-\u03b2-alanine in urine of workers occupationally exposed to 5-fluorouracil in a 5-fluorouracil-producing factory","volume":"3","author":"Boss","year":"1998","journal-title":"Biomarkers"},{"key":"10.1016\/j.toxlet.2018.10.007_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mrgentox.2005.07.008","article-title":"Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees","volume":"587","author":"Cavallo","year":"2005","journal-title":"Mutat. Res."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0015","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/JOM.0000000000000249","article-title":"Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings: a review of the evidences","volume":"56","author":"Connor","year":"2014","journal-title":"J. Occ. Environ. Med."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0020","unstructured":"D. Lgs. 9 aprile 2008, n.81. http:\/\/www.lavoro.gov.it\/documenti-e-norme\/."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1191\/1078155205jp155oa","article-title":"Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature","volume":"11","author":"Dranitsaris","year":"2005","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/01.ede.0000246827.44093.c1","article-title":"Nurses with dermal exposure to antineoplastic drugs: reproductive outcomes","volume":"18","author":"Fransman","year":"2007","journal-title":"Epidemiology"},{"key":"10.1016\/j.toxlet.2018.10.007_bib0035","unstructured":"Guidance for industry: bioanalytical method validation, FDA, US Department of Health and Human Services. 2001. http:\/\/www.fda.gov\/cder\/guidance\/4252fnl.pdf."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0040","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0045","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1007\/s00216-013-7269-3","article-title":"Liquid chromatography\u2013mass spectrometry for metabolic footprinting of co-cultures of lactic and propionic acid bacteria","volume":"405","author":"Honor\u00e9","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0050","unstructured":"Italian Guidelines. Provvedimento 5 agosto 1999. Documento di linee-guida per la sicurezza e la salute dei lavoratori esposti a chemioterapici antiblastici in ambiente sanitario, G.U. 236, 7.10.1999 http:\/\/www.gazzettaufficiale.it\/eli\/gu\/1999\/10\/07\/236\/sg\/pdf."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0055","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2146\/ajhp050529","article-title":"ASHP guidelines on handling hazardous drugs","volume":"63","author":"American Society of Health System Pharmacist (ASHP)","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0060","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jchromb.2017.06.028","article-title":"A review of high performance liquid chromatographic-mass spectrometricurinary methods for anticancer drug exposure of health care workers","volume":"1060","author":"Mathias","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.toxlet.2018.10.007_bib0065","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0070","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.jchromb.2010.02.011","article-title":"Biological monitoring of occupational exposure to 5-fluorouracil: urinary \u03b1-fluoro-\u03b2-alanine assay by high performance liquid tandem mass spectrometry in health care personnel","volume":"878","author":"Ndaw","year":"2010","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.toxlet.2018.10.007_bib0075","unstructured":"NIOSH: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (NIOSH), 2004. Alert: Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Healthcare Settings. DHHS (NIOSH). Publication N 2004-165 www.cdc.gov\/niosh\/docs\/2004-165\/."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0080","unstructured":"Occupational Safety and Health Administration (OSHA) (2011) Work precautions for handling hazardous drugs highlighted by NIOSH OSHA Joint Commission. www.osha.gov\/pls\/oshaweb\/owadisp.show_document?p_table=NEWS_RELEASES&p_id=19566 Occupational Safety and Health Administration (OSHA) Controlling Occupational Exposure to Hazardous Drugs. www.osha.gov\/SLTC\/hazardousdrugs\/controlling_occex_hazardousdrugs.html."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical pharmacokinetics of capecitabine","volume":"40","author":"Reigner","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00280-003-0642-8","article-title":"Pharmacokinetics of Capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer","volume":"52","author":"Reigner","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0095","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/bmc.559","article-title":"Assay of urinary alpha-fluoro-beta-alanine by gas chromatography-mass spectrometry for the biological monitoring of occupational exposure to 5-fluorouracil in oncology nurses and pharmacy technicians","volume":"20","author":"Rubino","year":"2006","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0100","first-page":"79","article-title":"Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil","volume":"36","author":"Sessink","year":"1994","journal-title":"JOM"},{"key":"10.1016\/j.toxlet.2018.10.007_bib0105","series-title":"Normal-phase chromatography, in: Introduction to modern liquid chromatography","first-page":"361","author":"Snyder","year":"2010"},{"key":"10.1016\/j.toxlet.2018.10.007_bib0110","series-title":"Introduction to Modern Liquid Chromatography","first-page":"253","article-title":"Reversed-phase chromatography for neutral samples","author":"Snyder","year":"2010"},{"key":"10.1016\/j.toxlet.2018.10.007_bib0115","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/annweh\/wxx065","article-title":"Monitoring surface contamination by antineoplastic drugs in Italian hospitals: performance-based hygienic guidance values (HGVs) project","volume":"618","author":"Sottani","year":"2017","journal-title":"Ann. Work Expo. Health"},{"first-page":"2003","year":"2014","series-title":"World Cancer Report","key":"10.1016\/j.toxlet.2018.10.007_bib0120"},{"key":"10.1016\/j.toxlet.2018.10.007_bib0125","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2147\/PPA.S36757","article-title":"The use of capecitabine in daily practice: a study on adherence and patients' experiences","volume":"6","author":"Timmers","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.toxlet.2018.10.007_bib0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.toxlet.2018.10.007_bib0135","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/1078155212459667","article-title":"Exposure of family members to antineoplastic drugia excreta of treated cancer patients","volume":"19","author":"Yuki","year":"2012","journal-title":"J. Oncol. Pharm. Pract."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427418319908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427418319908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T19:09:26Z","timestamp":1544123366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427418319908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":27,"alternative-id":["S0378427418319908"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2018.10.007","relation":{},"ISSN":["0378-4274"],"issn-type":[{"type":"print","value":"0378-4274"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new, sensitive and versatile assay for quantitative determination of \u03b1-fluoro-\u03b2-alanine (AFBA) in human urine by using the reversed-phase ultrahigh performance-tandem mass spectrometry (rp-UHPLC\u2013MS\/MS) system","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2018.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}